Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.
Scott-Algara D, Aboulker JP, Durier C, Badell E, Marcellin F, Prud'homme M, Jouanne C, Meiffredy V, Brun-Vezinet F, Pialoux G, Raffi F; ANRS-072 Trial Group. Scott-Algara D, et al. Among authors: durier c. Clin Exp Immunol. 2001 Nov;126(2):295-303. doi: 10.1046/j.1365-2249.2001.01680.x. Clin Exp Immunol. 2001. PMID: 11703374 Free PMC article. Clinical Trial.
Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP; ANRS 079 Study Group. Levy Y, et al. Among authors: durier c. AIDS. 2003 Feb 14;17(3):343-51. doi: 10.1097/00002030-200302140-00008. AIDS. 2003. PMID: 12556688 Clinical Trial.
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Launay O, et al. Among authors: durier c. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
Pialoux G, Hocini H, Pérusat S, Silberman B, Salmon-Ceron D, Slama L, Journot V, Mathieu E, Gaillard C, Petitprez K, Launay O, Chêne G; ANRS VAC14 Study Group. Pialoux G, et al. Vaccine. 2008 May 19;26(21):2657-66. doi: 10.1016/j.vaccine.2007.11.002. Epub 2007 Nov 26. Vaccine. 2008. PMID: 18068876 Clinical Trial.
Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. Fontas E, et al. Among authors: durier c. J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14. doi: 10.1097/QAI.0b013e318190018c. J Acquir Immune Defic Syndr. 2009. PMID: 19131886
56 results